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Juvenile Hyperlipemia 
WILLIAM W. MILLER, M.D., Professor of Pediatrics 
Asymptomatic hyperlipemia occurs in a signifi-
cant number of American children. It is important to 
recognize the condition during childhood because of 
its role as a risk factor in the early onset of coronary 
artery disease and because early dietary modification 
may prevent changes leading to premature heart dis-
ease. 
A predisposition to heart attack exists within 
families, and now there is significant documentation 
of familial aggregations of coronary atherosclerosis 
as a concomitant of genetically determined risk fac-
tors such as hyperlipemia, hypertension, and diabetes 
mellitus. 1 - 3 Of these three conditions, hyperlipemia, 
which often displays a clearly genetic component, is 
related most directly to the pathogenesis of athero-
sclerosis. 
The following review will present the character-
istics of juvenile hyperlipemia, note the known ge-
netic influences, document its prevalence in children 
in the United States, and present recommendations 
for diagnosis and management. 
Hyperlipemia is the manifestation of a variety of 
biochemical abnormalities producing hypercholester-
olemia and/or hypertriglyceridemia, both of which 
are associated with an increased risk of coronary 
artery disease in adults. Because hyperlipemia occurs 
in early childhood and may lead to coronary athero-
sclerosis, the identification and treatment of children 
with hyperlipemia should receive more attention than 
it does at present. The definition of hyperlipemia is 
indistinct; normal blood levels of cholesterol and tri-
glycerides are defined statistically by measurements 
in apparently healthy children. Although the levels 
can vary geographically and may be influenced by 
diet and other factors, "normal limits" have generally 
been based on 90th percentile fiducial limits calcu-
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lated from relatively small samples (Table I ).4 A di-
agnosis of hyperlipemia is justified if lipid or lipopro-
tein concentrations, measured after a 12-hour fast, 
are above these "riormal limits" on three separate 
occasions at least two weeks apart. Both cholesterol 
and triglyceride serum concentrations increase gradu-
ally throughout childhood and adolescence. Al-
though the studies are limited, the normal range of 
cholesterol levels appears to be relatively narrow ex-
cept during the first year of life when serum choles-
terol is especially affected by the type of fat in the 
diet; consequently, unless the parents are hyper-
lipemic, diagnostic and therapeutic decisions are best 
delayed until after six months or one year of age, 
when a more mixed source of dietary fat is usual and 
there is a diminished variation of serum lipid concen-
trations. The changes in serum triglyceride concen-
trations during childhood are less well defined than 
are those for cholesterol, although a gradual increase 
is commonly observed. In children with persistent 
hyperlipemia, serum lipoprotein should be estimated 
by electrophoresis, and a survey of other family mem-
bers is indicated. These additional studies can greatly 
facilitate a precise diagnosis when it is possible to 
demonstrate similar findings in a parent or sibling. 
The most widely used classification of hyper-
lipemic diseases is based upon the serum lipoprotein 
pattern since blood lipids are bound to lipoproteins. 
The term "hyperlipoproteinemia" is therefore often 
preferred over " hyperlipemia" or " hyperlipidemia." 
Six types of primary hyperlipoproteinemia are seen in 
adults; all except type III have been detected in child-
hood or adolescence. A useful classification of juve-
nile hyperlipoproteinemia is illustrated in the Figure. 
Hyperlipoproteinemia I, also known as familial 
hyperchylomicronemia or lipoprotein lipase defi-
ciency, is a rare autosomal recessive trait. The bio-
chemical defect is a deficiency of the enzyme, lipopro-
tein lipase. In homozygous children the disease is 
usually characterized by elevated cholesterol and tri-
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TABLE 1 
Upper Limits of " Normal" of Plasma Lipid and Lipoprotein Cholesterol Concentrations (mg/ 100 ml ) in Infants, Children and Adolescents 
AGE 
CORD BLOOD 
1-19 yr 
TOTAL 
CHOLESTEROL 
95 
230 
TRIGLYCERIDE 
65 
140 
glyceride levels, a deficiency of lipoprotein lipase ac-
tivity in post-heparin plasma or adipose tissue, chy-
lomicron uptake in the skin and reticuloendothelial 
tissue, abdominal pain, and pancreatitis which may 
be fatal. In children with xanthoma or pain the diag-
nosis is clinically obvious. However, in many children 
who are asymptomatic the diagnosis may be made 
LIPOPROTEIN LI POPROTE IN LIPOPROTEIN SERUM 
PHENOTYPE ELECTROPHORETIC ABNORMALITY CHOL. 
PATTERN 
1111 I I Chylomicrons t 
Chylomicrons 
IIA II 11 1 1 t LDL ttt 
Beta 
II II I I t LDL ttt 
Beta + Pre-Beta t VLDL 
IIB 
III II I Broad Beta 1 1 Abn LDL Abn e-VLDL Ht 
IV II II I I t VLDL + or -
Pre-Beta 
v 11 II I I Chylomicrons ttt 
Chylomicrons t VLDL 
+ Pre-Beta 
HD L C HOLESTE ROL 
LD L CHOLESTEROL MA LE FEMALE 
45 
170 
55 
65 
55 
70 
accidentally by a finding of milky plasma, hepatos-
plenomegaly, or lipemia retinalis. Premature athero-
sclerosis has not been documented in these patients; 
however, the other symptoms and debilitating nature 
of the disease make treatment mandatory. 
Hyperlipoproteinemia II, also know as familial 
hypercholesterolemia or familial hyperbetalipopro-
LIPIDS 
TRIGLY. 
tttt 
tt 
ttt 
ttt 
tttt 
PRIMARY SECONDARY 
Famil ial Diabetes mellitus 
hyperchylomicronemia 
Familial Hypothyroidism 
hypercholesterolemia Nephrotic syndrome 
Obstructive jaundice 
Fami 11 al Hypothyroidism 
hypercholesterolemia Nephrotic syndrome 
Obstructive jaundice 
Familial Hypothyroidism 
dysbetalipo-
proteinemia 
Familial Diabetes mellitus 
hyperglyceridemia Nephrotic syndrome 
Glycogenosis (III) 
Hypothyroidism 
Familial Diabetes mell i tus 
hypertriglyceridemia Nephrotic syndrome 
Pancreatitis 
Figure-Phenotypic classification o f hyperlipoproteinemias. 
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teinemia, is inherited as an autosomal dominant trait. 
It is the most common form of juvenile hyperlipemia 
a nd is associated with a high risk of premature coro-
nary artery disease. Hyperlipoproteinemia II ac-
counts for many adults with myocardial infarction. 
Biochemical abnormalities are now believed to be the 
result of an absence or deficiency of a low-density 
lipoprotein receptor on cell membranes.5·6 
The relatively common heterozygous form, hy-
perlipoproteinemia II A, has an estimated prevalence 
of four per thousand7; in a Seattle study approxi-
mately one out of every twenty adult survivors of 
myocardial infarction was found to have this condi-
tion8; in a similar study 38 of 64 survivors had abnor-
mal lipoprotein patterns.9 These hyperlipemic fa-
thers, all under 41 years of age, had 85 children of 
whom 30 also had hyperlipoproteinemia II. Hetero-
zygous infants have plasma cholesterol levels that are 
two to three times normal by the end of the first year 
of life. In matings between a heterozygous and a 
normal parent, the affected children can be identified 
at birth by cord-blood elevations of low-density lipo-
protein cholesterol to values greater than 41 mg/ JOO 
ml. 10 Tendinous xanthoma, corneal arcus, and coro-
nary artery disease develop in young adults, usually 
from 20 to 30 years of age. In about I 0% of children 
with type II disease, there are mildly elevated levels of 
very low-density lipoproteins and triglycerides along 
with elevations in low-density lipoprotein choles-
terol.11 This less common variation is classified as 
familial hyperlipoproteinemia II B.12 
Homozygous children, who inherit a double 
dose of the mutant gene, are much more severely 
affected; the disease is often suspected initially be-
cause of the strong family history of heart disease. 
Cholesterol levels, which may range from 500 to 1000 
mg/ JOO ml, are frequently markedly elevated even at 
birth, and corneal arcus and xanthoma appear before 
adolescence. Coronary artery disease is clinically ap-
parent before the age of 20 and survival beyond 30 is 
rare. 
In every family with a member who has experi-
enced a heart attack before the age of 50, serum 
cholesterol and triglyceride levels should be measured 
in all first-degree relatives. Those with normal lipid 
values can be reassured about lipid risk factors and a 
significant number of those with hyperlipemia can be 
identified and treated early. 
Hyperlipoproteinemia III , also known as "broad 
Beta disease," "floating Beta disease," or dysbetali-
poproteinemia, has not been detected in children, 
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as noted previously. Inheritance is probably either 
an autosomal recessive or an autosomal dominant 
with incomplete penetrance.13 The condition results 
in elevated levels of cholesterol and triglycerides with 
an abnormal cholesterol to triglyceride ratio in the 
very low-density lipoprotein .14 
Hyperlipoproteinemia IV, is relatively rare in 
children and is also referred to as familial hyper-
triglyceridemia or endogenous hypertriglyceridemia. 
Triglyceride levels are always elevated, ranging from 
150 to 1000 mg/ 100 ml, and in about 20% of patients 
the very low-density lipoprotein levels may result in a 
hypercholesterolemia, with levels up to 350 mg/ 100 
ml.15 Clinical findings commonly include non-ketotic 
diabetes and, less commonly, subcutaneous xan-
thoma. Obesity and hyperuricemia are frequent. A 
significant proportion of adults under the age of 50 
with angina or myocardial infarction have primary 
type IV disease. 15 The condition appears to be hetero-
geneous. The biochemical abnormality is not known, 
but studies suggest a defect in very low-density lipo-
proteinemia catabolism.16·17 It may occur in relatives 
of patients with type III or type V lipoprotein abnor-
malities13 and in some families genetic transmission 
follows an autosomal dominant pattern with delayed 
expression. 
Hyperlipoproteinemia V is rare in childhood. 
Triglyceride levels range from 500 to 6,500 mg/ 100 
ml and cholesterol varies from 150 to 1,500 mg/ 100 
ml. Clinical findings are similar to those with type I 
disease. Type V disease does not lead to premature 
atherosclerosis; it is frequently associated with obe-
sity, hyperuricemia, and abnormal glucose tolerance. 
The inheritance of the primary disease is not known; 
a family history of diabetes is common and there is a 
high prevalence of type IV disease in first-degree rela-
tives. 
Many chronic childhood diseases are associated 
with secondary hyperlipemia (Figure). Although in-
fants with hypothyroidism usually have normal lipids 
and lipoproteins, in older children hypothyroidism is 
often associated with hypercholesterolemia which 
can be reduced by adequate thyroid treatment. Most 
children with the nephrotic syndrome have hyper-
cholesterolemia, with close inverse correlations be-
tween cholesterol and albumin levels. In children 
treated by renal dialysis, the practice of feeding high 
fat diets to provide sufficient calories for growth may 
result in secondary hyperlipoproteinemia and accel-
eration of atherosclerosis. Children with hepatic gly-
cogenosis III have hyperlipoproteinemia, usually 
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with increases in very low-density lipoproteins. Since 
many of these children survive to adulthood, early 
modification of the hyperlipemia by diet is indicated. 
Children with obstructive liver disease often have 
hyperlipemia unless the disease is at an advanced 
stage. Diet a nd drug management of the hyper-
lipemia result in diminution in the symptoms and 
lesions of xanthomatosis. In adolescents and young 
adults other rare causes of hyperlipemia are preg-
nancy, alcoholism, adrenal disease, and the chronic 
administration of adrenal corticosteroid drugs. 
Dietary restriction and selection of fats is in-
dicated in all children with primary hyperlipemias 
(Table 2). Because skin xanthoma are diminished or 
eliminated in children undergoing treatment, it is rea-
sonable to conjecture that regression of vascular lipid 
deposits, with a concomitantly decreased risk of cor-
onary artery disease, also occurs. In type I disease a 
low-fat diet normalizes serum lipids and reduces or 
prevents abdominal pain and pancreatitis. In type II 
disease a low-fat, low-cholesterol diet with a high 
ratio of polyunsaturated to saturated fats normalizes 
lipids in type II A patients, reduces lipid levels signifi-
cantly in type II B children, and diminishes xanthoma 
in both. In type IV children a low-calorie, weight-
reduction diet is sufficient to normalize serum lipid. 
In children with type V disease a low fat, moderate 
cholesterol diet normalizes serum lipids and prevents 
abdominal pain. 
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A low-cholesterol diet, 100 to 150 mg/ 100 ml, is 
achieved by eliminating egg yolk, organ and fatty 
meats, and shellfish, substituting skim milk and low-
cholesterol margarine for whole milk and butter, us-
ing only cottage cheese among the cheeses and pro-
hibiting products with coconut oil in them.18 
Diet management alone is inadequate in 85% of 
type II children, and it is often necessary to u·se 
cholestyramine, a nonabsorbable anionic resin and 
bile acid sequestrant, which produces an exchange of 
chloride ions for bile acids in the intestine. The acids 
are excreted in the feces, and the reduction in enzyme 
product inhibition increases the endogenous metabo-
lism of cholesterol, resulting in diminished serum 
levels of very low-density and low-density lipoprotein 
cholesterol. In doses of 250 to 800 mg/ kg/ day, cho-
lestyramine does not cause malabsorption, although 
constipation, epigastric discomfort, and bloating are 
common. Beca use the drug absorbs fat, it can also 
produce mild steatorrhea and poor absorption of fat 
soluble vitamins. Its disagreeable taste is masked by 
using fruit juice or incorporating it into cookies. The 
surgical treatment of children with type II disease by 
partial ilea! bypass is not recommended at this time. 
In homozygous type II B children, the prognosis 
for effective reduction in serum lipids is poor. Low-
fat diets a nd large doses of cholestyramine, together 
with the administration of nicotinic acid may be ef-
fective.19 Nicotinic acid, however, is often poorly tol-
TABLE 2 
Treatment of Primary Juvenile Hyperlipemia 
TYPE DIET 
Low fat (10-15 g/ day) 
Medium chain triglyceride 
II A HETEROZYGOTE Low cholesterol (100-150 mg/day) 
High polyunsaturated/ 
saturated ratio (2/ I) 
II B HOMOZYGOTE Low cholesterol (100-150 mg/ day) 
High polyunsatu rated/ 
IV 
v 
saturated ratio (2/ 1) 
Low calorie weight control 
Low fat (20-30 g/ day) 
Moderate cholesterol 
(300-400 mg/ kg/ day) 
Medium chain triglyceride 
DRUG 
Cholestyramine 
(250- 800 mg/kg/ day) 
Cho lestyramine 
500-1500 mg/ kg/ day 
Nicotinic acid 
25-75 mg/ kg/ day 
EFFECT 
Normalizes lipids 
Prevents pain and pancreatitis 
Normal izes lipids. Reduction of 
cardiovascular risk possible 
Lowers lipids, Xanthoma diminish. 
Reduction of cardiovascular 
risk possible 
Norma lizes lipids. Reduction in 
cardiovascular risk possible 
Normalizes lipids prevents pain 
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erated because of such side-effects as flushing, gastro-
intestinal distress, temporary hyperuricemia, glucose 
intolerance, or hepatic dysfunction. 
Nationwide reductions in dietary fat and choles-
terol intake have been promulgated by various health 
organizations. Most advisors recommend a reduction 
of individual fat intake from 40% to 30% of the total 
calories and a decrease in cholesterol and saturated 
fats. 
Juvenile hyperlipemia is relatively common in 
the United States, and most affected children are 
asymptomatic. Measurements of serum cholesterol 
and triglycerides are indicated in all infants and chil-
dren in families with one or more members having a 
heart attack before the age of 50, because a signifi-
cant proportion of these children will have hyper-
lipemia and will require dietary restrictions, and 
some will need drug treatment. Early recognition and 
management of juvenile hyperlipemia may diminish 
the incidence or severity of coronary artery disease 
decades later. 
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